Fumikazu Yamazaki

Dr. Fumikazu Yamazaki


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2021 in The Journal of Dermatology
Verified
Journal Article
Open access
PDF file
FYFumikazu Yamazaki
Fumikazu Yamazaki
Psoriasis has long been known as a disease with many complications, but was attributed to diet and obesity. However, in recent years, psoriasis itself has been recognized as a series of systemic inflammatory diseases, and that the cytokines involved can induce a variety of other diseases. Individuals with psoriasis were also found to have higher incidences of cerebral and cardiovascular diseases and a younger age at death compared to healthy individuals. However, no clear guidelines have been defined regarding how much vascular lesion testing should be performed in patients with psoriasis. In this report, I attempt to unravel the objective data on psoriasis and its complications from various reviews and reports, and introduce the impact of biologics, which are currently the main treatment for psoriasis, on cardiac vascular disease.

10 October 2018 in The Journal of Dermatology
Verified
Journal Article
Open access
PDF file
AMAkimichi Morita
Akimichi Morita
FYFumikazu Yamazaki
Fumikazu Yamazaki
TMTakashi Matsuyama
Takashi Matsuyama
KTKenzo Takahashi
Kenzo Takahashi
SASatoru Arai
Satoru Arai
SKSusumu Kitamura
Susumu Kitamura
A phase 3, multicenter, open‐label, 52‐week study investigated the efficacy and safety of adalimumab 80 mg at week 0 followed by adalimumab 40 mg every other week (option to escalate to 80 mg when necessary) in Japanese patients with generalized pustular psoriasis (GPP). Adults (aged 15–75 years) with GPP, total skin score (overall erythema area, erythema area with pustules, and edema area) of 3 or more, and erythema with pustules (skin score, ≥1) based on the 2014 Japanese Dermatological Association severity index of GPP were enrolled. The primary efficacy end‐point was clinical response at week 16 (non‐responder imputation), defined as achieving remission (total skin score, 0) or improvement from baseline (reduction of ≥1 point from a baseline total skin score of 3 or ≥2 points from a baseline total skin score of ≥4). Of 10 enrolled patients (mean disease duration, 10.6 years), seven patients, including three with the dose escalated to 80 mg every other week before week 15, achieved clinical response at week 16, and five achieved clinical response at week 52. Mean change from baseline total GPP score was −4.6 at week 16 (n = 8) and −6.0 at week 52 (n = 5); change in total skin score was −3.1 (n = 8) and −4.2 (n = 5), respectively. Nine patients experienced one or more adverse events and three experienced serious adverse events. The most common adverse events were nasopharyngitis, pruritus and hypoalbuminemia. In conclusion, adalimumab was effective and well tolerated for up to 52 weeks in the treatment of Japanese patients with GPP.

1 March 2021 in Journal of Dermatological Science
Verified
Journal Article
Open access
SIShinichi Imafuku
Shinichi Imafuku
YKYasumasa Kanai
Yasumasa Kanai
KMKenta Murotani
Kenta Murotani
TNTakanobu Nomura
Takanobu Nomura
KIKei Ito
Kei Ito
TKTatsuyuki Kakuma
Tatsuyuki Kakuma
Plaque psoriasis significantly affects patients' health-related quality of life. To aid treatment decisions, not only objective assessment by physicians but also subjective assessment by patients is important. To assess the significance of Dermatology Life Quality Index (DLQI) evaluation at the time of biologics introduction in clinical practice in Japanese patients with plaque psoriasis. This was a single-arm, open-label, multicenter study. At baseline, Psoriasis Area and Severity Index (PASI) and DLQI scores were measured and stratified based on DLQI scores ≥6/≤5 and PASI scores ≤10/>10. Other patient-reported outcomes assessed included EQ-5D-5L, itch numerical rating scale (NRS), skin pain NRS, Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-8 (PHQ-8), Sleep Problem Index-II (SPI-II), and Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9). Of the 73 enrolled patients, 23 had PASI scores ≤10. Those with PASI/DLQI scores >10/≥6 had a significantly higher median PASI score than those with PASI/DLQI scores >10/≤5 (p = 0.0125). Regardless of PASI scores (>10/≤10), median itch NRS and GAD-7 scores were significantly higher in patients with DLQI scores ≥6 than in those with DLQI scores ≤5 (itch NRS, p = 0.0361 and p = 0.0086, respectively; GAD-7, p = 0.0167 and p = 0.0273, respectively). Patients with PASI/DLQI scores ≤10/≥6 had significantly higher skin pain NRS (p = 0.0292) and PHQ-8 (p = 0.0255) scores and significantly lower median SPI-II scores (p = 0.0137) and TSQM-9 Effectiveness domain scores (p = 0.0178) than those with PASI/DLQI scores ≤10/≤5. DLQI may be useful for assessing patients' concerns that cannot be identified by PASI alone while initiating biologics or switching from other biologics in clinical practice.

24 January 2023 in The Journal of Dermatology
Verified
Journal Article
Closed access
COChika Ohata
Chika Ohata
HAHisataka Anezaki
Hisataka Anezaki
SKSakae Kaneko
Sakae Kaneko
FOFusako Okazaki
Fusako Okazaki
KIKotaro Ito
Kotaro Ito
SIShinichi Imafuku
Shinichi Imafuku

3 December 2018 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
TMTomoko Matsuda
Tomoko Matsuda
FYFumikazu Yamazaki
Fumikazu Yamazaki
IUIkuko Ueda‐Hayakawa
Ikuko Ueda‐Hayakawa
NKNaotomo Kambe
Naotomo Kambe
HOHiroyuki Okamoto
Hiroyuki Okamoto

17 August 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FYFumikazu Yamazaki
Fumikazu Yamazaki
KTKazuya Takehana
Kazuya Takehana
ATAkihiro Tanaka
Akihiro Tanaka
YSYonsu Son
Yonsu Son
YOYoshio Ozaki
Yoshio Ozaki
HTHideaki Tanizaki
Hideaki Tanizaki
Psoriasis is a systemic inflammatory disease known to affect survival in the presence of cerebral or cardiovascular comorbidities. However, no clear guidelines have been defined regarding the extent of vascular lesion testing that should be performed in patients with psoriasis. We therefore performed coronary computed tomography angiography (CCTA) in 88 Japanese patients with psoriasis who visited Kansai Medical University Hospital between 2015 and 2019 and determined the ankle–brachial pressure index (ABI) for 44 of these patients. CCTA abnormalities were found in 39 of the 88 patients, and a need for treatment was identified in 14 patients. The prevalence of cardiovascular lesions in these patients was 15.9%, significantly higher than that in the healthy Japanese population (6.38% according to the Suita Study). In the 44 patients with results for both ABI and CCTA, the rates of CCTA vascular lesions were significantly higher in cases with ABIs indicating hard vessels or above than in cases with supple, normal, or slightly stiff vessels. This is the first report to show a correlation between CCTA and ABI in psoriasis patients. ABI was considered useful as a preliminary test before CCTA. The univariate analysis of the abnormal and normal CCTA groups showed that the prevalence differed significantly among patients with psoriatic arthritis, erythrodermic psoriasis, older age, pre-existing conditions, drinking, and hypertension. The multivariate analysis showed correlations with arthritic or erythrodermic psoriasis.